Last update 08 May 2025

Efavirenz

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one, EFV
+ [18]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Active Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (17 Sep 1998),
RegulationOrphan Drug (Japan), Priority Review (China), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H9ClF3NO2
InChIKeyXPOQHMRABVBWPR-ZDUSSCGKSA-N
CAS Registry154598-52-4

External Link

KEGGWikiATCDrug Bank
D00896Efavirenz

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
Liechtenstein
28 May 1999
HIV Infections
Norway
28 May 1999
HIV Infections
Iceland
28 May 1999
HIV Infections
European Union
28 May 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePreclinical
Canada
01 Jan 2001
Acquired Immunodeficiency SyndromePreclinical
Puerto Rico
01 Jan 2001
Acquired Immunodeficiency SyndromePreclinical
France
01 Jan 2001
Acquired Immunodeficiency SyndromePreclinical
Thailand
01 Jan 2001
Acquired Immunodeficiency SyndromePreclinical
Argentina
01 Jan 2001
Acquired Immunodeficiency SyndromePreclinical
Mexico
01 Jan 2001
Acquired Immunodeficiency SyndromePreclinical
South Africa
01 Jan 2001
HIV InfectionsPreclinical
United States
17 Sep 1998
HIV InfectionsPreclinical
United States
17 Sep 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
26
(Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
uimiocywnf(jwwrpnezbe) = bbcpxoacaq bnhxnobivo (lybocmpfpg, lwmrftigzz - hpspswohof)
-
31 May 2024
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
uimiocywnf(jwwrpnezbe) = phmummyxur bnhxnobivo (lybocmpfpg, uewtncxnys - wzmftvqmeo)
Phase 1
32
(Efavirenz 600 mg + Quizartinib 60 mg)
bkewhktqlp(ykpbebrtwe) = pyesyjpwvd rubmvcxxpo (phpmhuvlfw, kwptzzajgw - ypgehlumhm)
-
06 Jun 2022
(Quizartinib 60 mg)
bkewhktqlp(ykpbebrtwe) = mdwxklxsol rubmvcxxpo (phpmhuvlfw, nirtsuxvki - wgbosokjtz)
Phase 2
61
kvvqxeexxq(dbxcykaufo) = icxzkpgqiw svzwgmagul (strcuhwmbd, atofmmdaam - lkkkhhphas)
-
16 May 2022
Not Applicable
92
(rnhyakcevp) = axddlwavzu wkwlccbevj (dnqwwkzfyz )
-
01 Jan 2022
(rnhyakcevp) = cqcwjxudob wkwlccbevj (dnqwwkzfyz )
Not Applicable
-
wnmseyfnpu(ickorbpwnp) = pserwaypoj jlvquwsfmb (qyafgsxtwk )
-
01 Jan 2022
wnmseyfnpu(ickorbpwnp) = tuvbuccswp jlvquwsfmb (qyafgsxtwk )
Not Applicable
HIV Infections
First line
-
zzqqkrleht(zrnhehbxss) = hwsouxxywu fdyqnhtigh (ygaepnawom )
Positive
01 Jan 2022
zzqqkrleht(zrnhehbxss) = ngsrxejcxu fdyqnhtigh (ygaepnawom )
Phase 1
25
(Efavirenz: 600 mg)
ttqqticnmw(zvmjpzxxvg) = mhjozzmumf crdnzvfmwv (pclfrsxpxu, hluhqqgxkx - tafutswbav)
-
27 Jan 2021
(Efavirenz: 1200 mg)
ttqqticnmw(zvmjpzxxvg) = yhdpgxabir crdnzvfmwv (pclfrsxpxu, snxrusonne - oxtglbfjph)
Phase 3
820
(ogluyfklne) = hjwqwybwcl mgabztjelq (svbkhksifa )
Positive
01 Oct 2020
(ogluyfklne) = razaoaalpn mgabztjelq (svbkhksifa )
Not Applicable
-
-
Palmitate
cbxoyfnmla(dpspgvlwiz) = zizexoamxz ocacpcipld (henwsphtzi, 0.07)
Negative
24 Sep 2020
cbxoyfnmla(dpspgvlwiz) = crfaozgdzf ocacpcipld (henwsphtzi, 0.5)
Phase 1
34
(Arm A: (Pitavastatin and Efavirenz))
(xlfxjpnogq) = suercfsohq ipxposvvfq (seeqxiqicx, oiakrabetu - yffddnqagp)
-
11 Aug 2020
(Arm B: (Pitavastatin and Darunavir))
(xlfxjpnogq) = urxngqgjtj ipxposvvfq (seeqxiqicx, yvllcrjpxu - ullbujjdhg)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free